US 2015/0322137 A1Published application

Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof

AssigneeEvec Inc.

InventorsKenzo TAKADA, Kantou NAKAJIMA

Life of this patent

Estimating the term…

Abstract

The present invention provides a novel human-derived monoclonal antibody specifically binding to human metapneumovirus F protein and neutralizing the human metapneumovirus, and an antigen-binding fragment thereof. The present invention also provides a pharmaceutical composition comprising the antibody or an antigen-binding fragment thereof.

Claims41

Dependent claims

An antibody capable of specifically binding to human metapneumovirus F protein and neutralizing its biological activity, or an antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region wherein

(i) the heavy chain variable region comprises:
(a) the amino acid sequence of heavy chain CDR1 selected from the group consisting of the amino acid sequences of SEQ ID NOs:
3, 13, 23, 33, 43, 53, 63, 73, 83, 93,
103, 113, and 123 and amino acid sequences derived from any of these amino acid sequences by the deletion, substitution, insertion, and/or addition mutations of one to several amino acid residues,
(b) the amino acid sequence of heavy chain CDR2 selected from the group consisting of the amino acid sequences of SEQ ID NOs:
4, 14, 24, 34, 44, 54, 64, 74, 84, 94, 104, 114, and 124 and amino acid sequences derived from any of these amino acid sequences by the deletion, substitution, insertion, and/or addition mutations of one to several amino acid residues, and
(c) the amino acid sequence of heavy chain CDR3 selected from the group consisting of the amino acid sequences of SEQ ID NOs:
5, 15, 25, 35, 45, 55, 65, 75, 85, 95, 105, 115, and 125 and amino acid sequences derived from any of these amino acid sequences by the deletion, substitution, insertion, and/or addition mutations of one to several amino acid residues, and
(ii) the light chain variable region comprises:
(a) the amino acid sequence of light chain CDR1 selected from the group consisting of the amino acid sequences of SEQ ID NOs:
8, 18, 28, 38, 48, 58, 68, 78, 88, 98, 108, 118, and 128 and amino acid sequences derived from any of these amino acid sequences by the deletion, substitution, insertion, and/or addition mutations of one to several amino acid residues,
(b) the amino acid sequence of light chain CDR2 selected from the group consisting of the amino acid sequences of SEQ ID NOs:
9, 19, 29, 39, 49, 59, 69, 79, 89, 99, 109, 119, and 129 and amino acid sequences derived from any of these amino acid sequences by the deletion, substitution, insertion, and/or addition mutations of one to several amino acid residues, and
(c) the amino acid sequence of light chain CDR3 selected from the group consisting of the amino acid sequences of SEQ ID NOs:
10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, and 130 and amino acid sequences derived from any of these amino acid sequences by the deletion, substitution, insertion, and/or addition mutations of one to several amino acid residues.

12 more elements

Dependencies are inferred from the claim text.

patentgrep

Loading patent…

Abstract

(i) the heavy chain variable region comprises:
(a) the amino acid sequence of heavy chain CDR1 selected from the group consisting of the amino acid sequences of SEQ ID NOs:
3, 13, 23, 33, 43, 53, 63, 73, 83, 93,
103, 113, and 123 and amino acid sequences derived from any of these amino acid sequences by the deletion, substitution, insertion, and/or addition mutations of one to several amino acid residues,
(b) the amino acid sequence of heavy chain CDR2 selected from the group consisting of the amino acid sequences of SEQ ID NOs:
4, 14, 24, 34, 44, 54, 64, 74, 84, 94, 104, 114, and 124 and amino acid sequences derived from any of these amino acid sequences by the deletion, substitution, insertion, and/or addition mutations of one to several amino acid residues, and
(c) the amino acid sequence of heavy chain CDR3 selected from the group consisting of the amino acid sequences of SEQ ID NOs:
5, 15, 25, 35, 45, 55, 65, 75, 85, 95, 105, 115, and 125 and amino acid sequences derived from any of these amino acid sequences by the deletion, substitution, insertion, and/or addition mutations of one to several amino acid residues, and
(ii) the light chain variable region comprises:
(a) the amino acid sequence of light chain CDR1 selected from the group consisting of the amino acid sequences of SEQ ID NOs:
8, 18, 28, 38, 48, 58, 68, 78, 88, 98, 108, 118, and 128 and amino acid sequences derived from any of these amino acid sequences by the deletion, substitution, insertion, and/or addition mutations of one to several amino acid residues,
(b) the amino acid sequence of light chain CDR2 selected from the group consisting of the amino acid sequences of SEQ ID NOs:
9, 19, 29, 39, 49, 59, 69, 79, 89, 99, 109, 119, and 129 and amino acid sequences derived from any of these amino acid sequences by the deletion, substitution, insertion, and/or addition mutations of one to several amino acid residues, and
(c) the amino acid sequence of light chain CDR3 selected from the group consisting of the amino acid sequences of SEQ ID NOs:
10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, and 130 and amino acid sequences derived from any of these amino acid sequences by the deletion, substitution, insertion, and/or addition mutations of one to several amino acid residues.

12 more elements